删除USP38改善了心力衰竭小鼠的扩张性功能障碍和心律失常,这些小鼠具有保存的喷射分数
Hong Meng1, Zongze Qu1, Liang Guo1
1Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, Hubei, People's Republic of China; Cardiovascular Research Institute of Wuhan University, Wuhan, Hubei, People's Republic of China; Hubei Key Laboratory of Cardiology, Wuhan, Hubei, People's Republic of China.
删除USP38通过抑制HIPK2.2,减少心力衰竭中心室节律失常,通过抑制HFpEF小鼠. USP38是与HFpEF相关的腹功能障碍和静脉动脉的潜在治疗标.
科学领域:
- 心脏病学 心脏病学
- 分子生物学分子生物学
- 遗传学 遗传学 是一个
背景情况:
- 静脉节律失常 (VAs) 增加了心力衰竭的死亡率与保存的喷射分数 (HFpEF).
- 乌比奎丁特异性蛋白酶38 (USP38) 与心脏电力障碍有关.
研究的目的:
- 在HFpEF.EF的小鼠模型中调查USP38在VA中的作用.
主要方法:
- 使用心脏特异性的USP38淘汰和转基因小鼠.
- 诱导HFpEF通过uninephrectomy,阿尔多注入和高盐摄入.
- 进行了心声回声学,电生理学,组织学和分子分析.
主要成果:
- USP38淘汰赛改善了HFpEF诱导的左心室缩,扩张功能障碍和VA.
- 删除USP38抑制了HIPK2的激活,减少了LV纤维化,并增加了连接素43.
- USP38过度表达恶化了HFpEF表型和VA易感性.
结论:
- USP38淘汰赛通过抑制HIPK2激活来缓解与HFpEF相关的VA.
- USP38被确定为HFpEF扩张功能障碍和VA的新疗法标.
更多相关视频
03:42Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
11:50High-frequency High-resolution Echocardiography: First Evidence on Non-invasive Repeated Measure of Myocardial Strain, Contractility, and Mitral Regurgitation in the Ischemia-reperfused Murine Heart
Published on: July 9, 2010